Ketamine, a widely used anesthetic that is also used as a psychedelic drug, has been approved in recent years as a treatment for depression. The journal Science has published a study that sheds light on how the substance works. The researchers, from Cornell and Stanford universities in the United States and the University of Tokyo in Japan, show that ketamine reduces depression symptoms by promoting neuroplasticity in the brain, a process in which nerve cells form new connections with neighboring nerve cells.
The Research Method
Ketamine, a versatile substance known for its psychedelic properties and its use in anesthesia, was recently approved as a treatment for depression. A groundbreaking study published in the renowned journal Science delves into the complex workings of its effects and sheds light on its mechanism of action.
To replicate depression symptoms in mice, the researchers exposed them to three weeks of stress, either by confining them in cramped spaces or by injecting the stress hormone corticosterone. The mice showed classic signs of despair resembling depression, such as a lack of preference for sweetened water and reduced resistance in a tail-suspension test. Unlike traditional antidepressants, which often take weeks to show their effects, ketamine demonstrates its effectiveness within hours. In the study, just three hours after receiving ketamine, the mice showed normalized behavior free of despair.
Led by Conor Liston, the research team hypothesized that ketamine’s rapid antidepressant action stems from promoting new connections, or synapses, between neurons (nerve cells in the brain). When the neurons were examined after ketamine treatment, particularly during the phase of behavioral improvement, no changes were seen in the dendritic spines, the small protrusions essential for forming synapses. This observation suggests that ketamine’s immediate effects on behavior precede synaptic changes, and it highlights the complexity of its mechanism.
Neural Change
Although the initial behavioral change does not directly involve new synapses, their role becomes clear in sustaining the positive changes over time. About 12 hours after treatment, new dendritic spines emerged in the prefrontal cortex, a region associated with complex cognition. To confirm the importance of these spines in maintaining the improved behavior, the researchers selectively eliminated them after ketamine was administered, which led to a return of depression-like symptoms in the mice.
While the exact mechanism behind ketamine’s rapid behavioral effect remains elusive, the study underscores the central role of new synapses in sustaining its antidepressant effects over the long term. This breakthrough paves the way for innovative depression treatments that harness similar pathways in the brain, offering hope for improved therapeutic strategies in mental health care.
The Good News
We are only at the beginning of the journey to discover new treatments for mental health disorders, and we are only starting to understand what really happens in our brains and what “mental disorders” actually are. From ketamine, which has already been approved by health ministries around the world, to other psychedelics such as MDMA, psilocybin and LSD, which have been granted breakthrough therapy status on an expedited path to FDA approval, there is a lot to look forward to!
About Ketamine Treatment at Stella USA
Interested in treatment for yourself or someone you love?
Leave your details for a callback or call us
